The Nebuliser Devices industry trends over the past 18 months reflect a dynamic market driven by technological innovation and evolving healthcare demands. Strategic partnerships have gained momentum, with players like Philips and ResMed collaborating with digital health firms to integrate IoT-enabled features into nebulisers, enabling remote patient monitoring. Mergers & acquisitions have also accelerated, as seen in the acquisition of a prominent nebuliser startup by a global medtech giant to bolster its home healthcare portfolio. Product launches highlight a shift toward compact, silent, and energy-efficient devices, with companies like Omron and Pari introducing models featuring AI-driven dosage optimization. Regulatory bodies, including the FDA and EMA, have updated guidelines to streamline approvals for connected nebuliser systems, fostering faster market entry. Meanwhile, consumer trends underscore a growing preference for home-based respiratory care, spurred by post-pandemic healthcare paradigms. Funding rounds in 2024, such as a $30M Series C secured by a U.S.-based nebuliser innovator, signal investor confidence in R&D for portable, affordable devices. These developments position the market for sustained growth, with a focus on patient-centric design and telehealth integration.
